TrialThe oncologist2021

Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.

John R Zalcberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.